ANL 31.81 Decreased By ▼ -0.40 (-1.24%)
ASC 19.19 Increased By ▲ 0.54 (2.9%)
ASL 28.10 Increased By ▲ 1.65 (6.24%)
AVN 90.70 Decreased By ▼ -0.65 (-0.71%)
BOP 8.50 Increased By ▲ 0.29 (3.53%)
BYCO 12.83 Increased By ▲ 0.99 (8.36%)
DGKC 128.60 Increased By ▲ 2.60 (2.06%)
EPCL 47.80 Decreased By ▼ -0.40 (-0.83%)
FCCL 24.37 Increased By ▲ 0.41 (1.71%)
FFBL 26.60 Decreased By ▼ -1.30 (-4.66%)
FFL 17.85 Increased By ▲ 0.06 (0.34%)
HASCOL 11.75 Increased By ▲ 0.30 (2.62%)
HUBC 78.51 Increased By ▲ 0.21 (0.27%)
HUMNL 8.68 Increased By ▲ 0.04 (0.46%)
JSCL 24.60 Decreased By ▼ -0.05 (-0.2%)
KAPCO 44.01 Decreased By ▼ -0.74 (-1.65%)
KEL 4.22 Increased By ▲ 0.03 (0.72%)
LOTCHEM 15.85 Decreased By ▼ -0.46 (-2.82%)
MLCF 48.90 Increased By ▲ 2.20 (4.71%)
PAEL 36.75 Increased By ▲ 0.55 (1.52%)
PIBTL 11.40 Increased By ▲ 0.36 (3.26%)
POWER 10.59 Increased By ▲ 0.51 (5.06%)
PPL 94.50 Increased By ▲ 4.30 (4.77%)
PRL 27.39 Increased By ▲ 1.14 (4.34%)
PTC 13.42 Decreased By ▼ -0.58 (-4.14%)
SILK 1.62 Increased By ▲ 0.04 (2.53%)
SNGP 50.48 Increased By ▲ 2.28 (4.73%)
TRG 162.50 Decreased By ▼ -6.00 (-3.56%)
UNITY 48.45 Decreased By ▼ -0.94 (-1.9%)
WTL 4.23 Decreased By ▼ -0.03 (-0.7%)
BR100 5,331 Increased By ▲ 48.9 (0.93%)
BR30 27,772 Increased By ▲ 170.83 (0.62%)
KSE100 48,726 Increased By ▲ 421.36 (0.87%)
KSE30 19,647 Increased By ▲ 168.7 (0.87%)

Coronavirus vaccine to enter late-stage trial by July end: Researchers

  • Volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus
03 Jul 2020

(Karachi) Coronavirus vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday.

The news comes as Moderna Inc, which is at the forefront of the country’s vaccine development efforts, reiterated earlier in the day that a late-stage trial with 30,000 volunteers would begin this month.

World's first inactivated Covid-19 vaccine produces antibodies: Chinese experts

“We may be able to at least know whether we are dealing with a safe and effective vaccine by the early winter, late winter, (or) beginning of 2021,” Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview to JAMA Network.

According to the firm, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.

AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO

In June, China National Biotec Group (CNBG) announced that their inactivated COVID-19 vaccine had passed phase one and two clinical trials.

The vaccine showed no "serious adverse reactions" with all volunteers generating antibodies after two doses in 28 days, the company said.